Biogen (BIIB) announced that BIIB122, a LRRK2 inhibitor for Parkinson’s disease developed in collaboration with Denali Therapeutics, Phase 2b LUMA study has fully enrolled with a readout expected in 2026. Today Biogen also announced that it plans to host a series of investor events to highlight the development pipeline. Biogen plans to hold the first virtual event on June 11 at 10 a.m. ET with a focus on felzartamab and rare disease. “Biogen does not intend to disclose new clinical data on the call,” it stated.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: